To characterize the pathway underlying the effect of Pir-B, IL-6 was administered at the optimal dose (20 ng/ml) in a co-culture of CD4+ T cells and DCs isolated from 5-week tumor-bearing mice. The gene discussed is CD4; the disease is neoplasm.